ArticleJournal of ovarian research2025
Global burden of ovarian cancer attributable to high BMI, 1990-2021: spatiotemporal trends, risk factors, frontier analysis, and projections to 2036 based on GBD 2021 study.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDespite the well-established link between elevated body mass index (BMI) and ovarian cancer, comprehensive global assessments of the attributable burden remain scarce. Using the Global Burden of Disease (GBD) 2021 database, we quantified deaths and disability-adjusted life years (DALYs) from ovarian cancer due to high BMI between 1990 and 2021 and delineated spatiotemporal trends to inform targeted prevention.
methodsWe analyzed GBD 2021 data for 204 countries and territories. Specifically, deaths and DALYs from ovarian cancer attributable to elevated BMI were quantified. Temporal trends were summarized with estimated annual percentage change (EAPC). Trends were examined with Joinpoint, decomposition, frontier, and predictive analyses.
resultsFrom 1990 to 2021, global deaths from ovarian cancer attributable to high BMI rose from 6,850 (95% UI 1,423–12,865) to 17,344 (4,141–30,810), a 153% increase; the age-standardized mortality rate (ASMR) grew by 17% to 0.38 per 100,000 (EAPC 0.40; 95% CI 0.32–0.47). Corresponding DALYs increased from 188,874 (38,401–355,691) to 477,248 (113,449–840,002), pushing the age-standardized DALY rate (ASDR) up 21% to 10.56 per 100,000 (EAPC 0.51; 0.45–0.57). Decomposition showed population growth contributed 57.58% of the net rise in deaths, ageing 25.26% and epidemiological change 17.16%. Only the high-SDI quintile exhibited declining rates; low- and middle-SDI regions sustained increases > 3% per year. Autoregressive Integrated Moving Average (ARIMA) model projections indicate both ASMR and ASDR will continue to climb until 2036.
conclusionsThe BMI-attributable ovarian-cancer burden is rising, particularly among women aged 40–79 years, and urgently requires multisectoral fiscal, screening, and lifestyle interventions tailored to national SDI levels.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.